# Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

> **NCT04137224** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 27 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** IgPro20
- **BIOLOGICAL:** IgPro10

## Key facts

- **NCT ID:** NCT04137224
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-05-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137224, "Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04137224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*